AbCellera Biologics Inc. (ABCL)

NASDAQ: ABCL · IEX Real-Time Price · USD
4.030
-0.020 (-0.49%)
Apr 17, 2024, 1:57 PM EDT - Market open
-0.49%
Market Cap 1.18B
Revenue (ttm) 38.03M
Net Income (ttm) -146.40M
Shares Out 292.78M
EPS (ttm) -0.51
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 440,016
Open 4.060
Previous Close 4.050
Day's Range 4.010 - 4.150
52-Week Range 3.870 - 8.050
Beta 0.36
Analysts Strong Buy
Price Target 19.00 (+371.46%)
Earnings Date May 7, 2024

About ABCL

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; and a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets, as well as ... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Dec 11, 2020
Employees 586
Stock Exchange NASDAQ
Ticker Symbol ABCL
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for ABCL stock is "Strong Buy." The 12-month stock price forecast is $19.0, which is an increase of 371.46% from the latest price.

Price Target
$19.0
(371.46% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024.

9 days ago - Business Wire

AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera (Nasdaq: ABCL) will announce its first quarter 2024 financial results on Tuesday, May 7, 2024, and hold an earnings conference call at...

13 days ago - Business Wire

AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the Bloom Burton Healthcare Conference on Tuesday, Apr...

4 weeks ago - Business Wire

AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera (Nasdaq: ABCL) and Biogen Inc. (Nasdaq: BIIB) have entered into a strategic collaboration to discover antibodies for a novel target th...

Other symbols: BIIB
5 weeks ago - Business Wire

AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera (Nasdaq: ABCL) today announced that its scientists will present four posters with data from its T-cell engager programs and platform a...

6 weeks ago - Business Wire

AbCellera Announces Resignation of Board Member

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera (Nasdaq: ABCL) today announced that Peter Thiel has notified the Company of his intention to resign from the Company's Board of Direct...

7 weeks ago - Business Wire

AbCellera to Present at Upcoming Investor Conferences in March

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the following investor conferences: 44th Annual TD Cow...

7 weeks ago - Business Wire

AbCellera Reports Full Year 2023 Business Results

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera (Nasdaq: ABCL) today announced financial results for the full year 2023. All financial information in this press release is reported i...

2 months ago - Business Wire

AbCellera to Report Full Year 2023 Financial Results on February 20, 2024

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera (Nasdaq: ABCL) will announce its full year 2023 financial results on Tuesday, February 20, 2024, and hold an earnings conference call ...

3 months ago - Business Wire

AbCellera to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the 42nd Annual J.P. Morgan Healthcare Conference on W...

4 months ago - Business Wire

AbCellera to Present at the Piper Sandler 35th Annual Healthcare Conference on November 30, 2023

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at the Piper Sandler 35th Annual Healthcare Conference on November 30, 2023.

5 months ago - Business Wire

AbCellera Presents New Data on Two T-Cell Engager Programs at SITC 2023

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Presents New Data on Two T-Cell Engager Programs at SITC 2023.

5 months ago - Business Wire

AbCellera Reports Q3 2023 Business Results

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Q3 2023 Business Results.

5 months ago - Business Wire

Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology

WILMINGTON, Del. & VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology...

5 months ago - Business Wire

AbCellera to Present at the Jefferies London Healthcare Conference on November 14, 2023

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at the Jefferies London Healthcare Conference on November 14, 2023.

6 months ago - Business Wire

AbCellera to Report Third Quarter 2023 Financial Results on November 2, 2023

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report Third Quarter 2023 Financial Results on November 2, 2023.

6 months ago - Business Wire

AbCellera Announces Two T-Cell Engager Presentations at SITC 2023

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Two T-Cell Engager Presentations at SITC 2023.

7 months ago - Business Wire

AbCellera Expands Multi-Target Antibody Discovery Collaboration with Regeneron

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Expands Multi-Target Antibody Discovery Collaboration with Regeneron.

7 months ago - Business Wire

AbCellera Announces Collaboration with Incyte to Accelerate the Discovery and Development of Therapeutic Antibodies in Oncology

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Collaboration with Incyte to Accelerate the Discovery and Development of Therapeutic Antibodies in Oncology.

7 months ago - Business Wire

AbCellera Reports Q2 2023 Business Results

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Q2 2023 Business Results.

9 months ago - Business Wire

AbCellera Announces that the U.S. Patent Trial and Appeal Board Has Denied Berkeley Lights' Request for Rehearing

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces that the U.S. Patent Trial and Appeal Board Has Denied Berkeley Lights' Request for Rehearing.

9 months ago - Business Wire

AbCellera to Report Second Quarter 2023 Financial Results on August 3, 2023

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report Second Quarter 2023 Financial Results on August 3, 2023.

10 months ago - Business Wire

Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera

GHENT, Belgium--(BUSINESS WIRE)--Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced that it has entered into a research collabora...

10 months ago - Business Wire

AbCellera to Present at the Goldman Sachs 44th Annual Global Healthcare Conference on June 13, 2023

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at the Goldman Sachs 44th Annual Global Healthcare Conference on June 13, 2023.

11 months ago - Business Wire

AbCellera Partners with the Governments of Canada and British Columbia to Advance Drug Development Capabilities and Infrastructure that Will Accelerate Innovative Medicines to Patients

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera (Nasdaq: ABCL) today announced a CA$701 million co-investment with the Governments of Canada and British Columbia to build new capabil...

11 months ago - Business Wire